DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04334317 (ClinicalTrials.gov)	October 21, 2020	30/3/2020	Effect of TAK-071 on Falls in Participants With Parkinson Disease (PD)	A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls	Parkinson's Disease	Drug: TAK-071;Drug: Placebo	Takeda	Michael J. Fox Foundation for Parkinson's Research	Recruiting	40 Years	85 Years	All	64	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04334317
(ClinicalTrials.gov)

October 21, 2020

30/3/2020

Effect of TAK-071 on Falls in Participants With Parkinson Disease (PD)

A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls

Parkinson's Disease

Drug: TAK-071;Drug: Placebo

Takeda

Michael J. Fox Foundation for Parkinson's Research

Recruiting

40 Years

85 Years

All

Phase 2

United States